The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active pharmaceutical industrial base to better understand the pharmaceutical supply chain and how it has changed since the COVID-19 pandemic. The assessment is based on a survey conducted last winter. The study will inform federal strategies and funding decisions related to the API supply chain and raise awareness of potential supply chain issues, such as the current limited domestic manufacturing capabilities and other potential issues. The study will survey more than 200 companies, including manufacturers, distributors, suppliers and customers. A Bureau of Industry and Security webpage answers FAQs about the project.
 

Related News Articles

Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…
Headline
The U.S. and China reached a joint agreement to temporarily reduce tariffs for 90 days, the White House announced May 12. Both countries will lower tariffs by…
Headline
AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients…
Headline
A JAMA Internal Medicine study published April 7 examined the effects of changing the default prescription lengths for statins, which are cholesterol-lowering…